EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells

Elisa Moraga, Núria Climent, Alejandro Sánchez-Molina, Sònia Vicens-Artés, María José Maleno, Gabriel Valero López, Carlos Galera Peñaranda, Juan Ambrosioni, José M Miró, Josep Mallolas, Helena Albendín-Iglesias, José Alcamí und 1 weitere

PLOS Pathogens · 2026

DOI: 10.1371/journal.ppat.1014266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Elisa Moraga und 12 weiteren Autor:innen. Beteiligte Einrichtung: AIDS and HIV Infection Group, Fundació de Recerca Clínic Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelon…. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, HIV Infections, HIV-1, Fingolimod Hydrochloride. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mr. Javier Moreno, Fondo de Investigación Sanitaria, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fingolimod, a treatment for multiple sclerosis (MS), decreases autoreactive lymphocytes by lymph node sequestration. In vitro , fingolimod decreases HIV-1 infection and viral reservoir (VR) through SAMHD1 phosphorylation inhibition and reducing lymphocyte activation and CD4 expression. We identified an exceptional MS patient infected with HIV-1 (HIV+ MS+) while on fingolimod therapy and we have analyzed its impact on HIV-1 infection in vivo and ex vivo .

Methods

The case was the HIV+ MS+ patient. Controls were 20 PWH (HIV+ MS-), five HIV-negative donors (HIV-MS) and three HIV-negative MS patients treated with fingolimod (HIV-MS+), as the case reported. VR was quantified by IPDA and HIV-1 intracellular RNAs (icRNAs) by ddPCR in peripheral blood CD4 + T-cells. CD4 + T-cells were infected in vitro with an NL4.3-Renilla strain. Immunophenotype, activation markers and phosphorylated SAMHD1 levels were determined by flow cytometry.

Findings

At diagnosis, HIV+ MS+ viral load was nine-fold lower than HIV+ MS- treated at similar Fiebig stage. One year after ART, HIV+ MS+ showed lower intact and defective VR than the HIV+ MS- control group (28-and six-fold decrease respectively). After three years on ART no intact proviruses were detected in HIV+ MS+ . HIV-1 in vitro infection was decreased in HIV+ MS+ and HIV- MS + vs HIV+ MS- and HIV-MS-. CD4 + T-cells levels from fingolimod treated patients were lower and showed decreased CD4 expression, lymphocyte activation and SAMHD1 phosphorylation vs HIV- MS-. icRNAs were significantly increased after T-cell activation in the HIV+ MS-, while they were barely detected at resting and activated HIV+ MS+ CD4 + T-cells.

Conclusions

We describe a strong restriction to HIV-1 infection and replication in vivo and ex vivo leading to indetectable intact VR in HIV+ MS+ after three years of ART. Potential mechanisms of restriction are CD4 downregulation, T-cell activation inhibition, and SAMHD1 activity enhancement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD4-Positive T-LymphocytesHIV InfectionsHIV-1Fingolimod HydrochlorideMultiple SclerosisImmunosuppressive AgentsHumansFemaleAdultMaleViral LoadSAM Domain and HD Domain-Containing Protein 1Middle AgedLymphocyte Activation

Substanzen

Fingolimod HydrochlorideImmunosuppressive AgentsSAMHD1 protein, humanSAM Domain and HD Domain-Containing Protein 1

Autor:innen und Institutionen

  • AIDS and HIV Infection Group, Fundació de Recerca Clínic Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
  • Department of Medicine, Universitat de Barcelona (UB), Barcelona, Spain.
  • Centro de Investigación Biomédica en Red sobre Enfermedades Infecciosas CIBER (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca/IMIB, CSUR Multiple Sclerosis and Clinical Neuroimmunology Unit, Murcia, Spain.
  • Hospital Clínico Universitario Virgen de la Arrixaca/ IMIB, HIV Unit, Murcia, Spain.
  • Infectious Diseases Service, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Sonsoles Sánchez-Palomino

Förderung

  • Mr. Javier Moreno
  • Fondo de Investigación Sanitaria
  • Instituto de Salud Carlos III
  • Institut d’Investigacions Biomèdiques August Pi i Sunyer
  • ViiV Healthcare
  • Janssen
  • Gilead

Zitieren

APA

Moraga, E., Climent, N., Sánchez-Molina, A., Vicens-Artés, S., Maleno, M. J., Valero López, G., Galera Peñaranda, C., Ambrosioni, J., Miró, J. M., Mallolas, J., Albendín-Iglesias, H., Alcamí, J., & Sánchez-Palomino, S. (2026). Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014266

Vancouver

Moraga E, Climent N, Sánchez-Molina A, Vicens-Artés S, Maleno MJ, Valero López G, et al. Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014266

BibTeX
@article{Moraga2026,
  author = {Moraga, Elisa and Climent, Núria and Sánchez-Molina, Alejandro and Vicens-Artés, Sònia and Maleno, María José and Valero López, Gabriel and Galera Peñaranda, Carlos and Ambrosioni, Juan and Miró, José M and Mallolas, Josep and Albendín-Iglesias, Helena and Alcamí, José and Sánchez-Palomino, Sonsoles},
  title = {Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells},
  journal = {PLOS Pathogens},
  year = {2026},
  doi = {10.1371/journal.ppat.1014266}
}
Kostenlos starten →